Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 64 Carboplatin 63 Paclitaxel 54 Magnetic Resonance Spectroscopy 45 Specimen Handling 43 Cisplatin 43 Gemcitabine 35 Bevacizumab 31 Docetaxel 30 Doxorubicin 29 Leucovorin 28 Fluorouracil 27 Dexamethasone 27 Cyclophosphamide 26 Pemetrexed 25 Radiation 23 Oxaliplatin 23 Radiotherapy 22 Etoposide 22 durvalumab 21 Nivolumab 21 Letrozole 21 Vincristine 20 Rituximab 20 Irinotecan 20 Taxes 19 Prednisone 19 Capecitabine 19 Lenalidomide 18 130-nm albumin-bound paclitaxel 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × remibrutinib × 30 days × Clear all

NCT06744920 2026-06-01

RELIEVE

Novartis

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡